CardioLogs ECG Analysis Platform vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CardioLogs ECG Analysis Platform

by Cardiologs Technologies (now part of Philips)

EchoNext

by Pathway Labs

AI Verdict

Both CardioLogs ECG Analysis Platform and EchoNext utilize AI for ECG analysis in cardiology, making them adjacent in their core technology and specialty. CardioLogs focuses on comprehensive arrhythmia detection from various monitoring devices, while EchoNext specializes in identifying hidden structural heart disease from standard 12-lead ECGs, suggesting different primary use cases for clinicians.

Choose CardioLogs ECG Analysis Platform if…

Choose CardioLogs ECG Analysis Platform if your primary need is rapid, high-volume, and comprehensive arrhythmia detection and diagnosis from a variety of cardiac monitoring devices, including Holters and smartwatches. Its cloud-based AI is ideal for practices needing efficient workflow and multi-device compatibility for diverse ECG data analysis.

View CardioLogs ECG Analysis Platform →

Choose EchoNext if…

Choose EchoNext if your focus is on utilizing standard 12-lead ECGs to non-invasively screen for and detect hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension. This tool is best suited for practices aiming to identify underlying cardiac conditions beyond arrhythmias.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CardioLogs ECG Analysis Platform	EchoNext
Pricing	Contact sales for customized quote	Starts at $600/month
Deployment	Cloud-based (SaaS)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CardioLogs ECG Analysis Platform

CardioLogs emphasizes a user-friendly interface, remote access, and multi-device compatibility, suggesting a broader and more flexible approach to usability. EchoNext's deployment through the OpenEvidence platform implies a specific integration, which might be less flexible for some users.

Clinical Value

EchoNext

EchoNext has demonstrated superior accuracy in detecting structural heart disease compared to cardiologists, even those assisted by AI, and has been credited with guiding care that led to a heart transplant. CardioLogs focuses on arrhythmia detection and reduction of false positives, which is valuable but not as broadly impactful as detecting hidden structural heart disease.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, offering clarity for potential buyers. CardioLogs requires contacting sales for a customized quote, making its pricing less transparent and potentially more variable.

Enterprise Readiness

CardioLogs ECG Analysis Platform

CardioLogs, as a Philips solution, benefits from the robust infrastructure and established enterprise relationships of a large healthcare technology company. Its cloud-based SaaS deployment and ISO/IEC 27001 certification also indicate strong enterprise readiness. EchoNext's deployment through OpenEvidence is a good start, but CardioLogs' integration with a major player like Philips suggests a more mature enterprise offering.

Innovation

EchoNext

EchoNext represents a significant innovation by being the first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a capability that traditionally required more expensive and less accessible tests like echocardiograms. CardioLogs, while innovative in its AI-powered arrhythmia detection and multi-device compatibility, entered the market earlier and focuses on a more established area of ECG analysis.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details about the depth or accessibility of support and documentation for either tool. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CardioLogs ECG Analysis Platform	EchoNext
Tool Name	CardioLogs ECG Analysis Platform	EchoNext
Company	Cardiologs Technologies (now part of Philips)	Pathway Labs
Tagline	Reinventing cardiology diagnostics with medical-grade AI and cloud technology.	How's your heart?
Key Features (Primary Focus)	AI-Powered ECG Analysis for rapid, accurate, and efficient analysis of ECG data from various cardiac monitoring devices, aiding physicians in arrhythmia detection and diagnosis.	AI-powered ECG analysis to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, utilizing standard 12-lead ECGs.

Videos

Demos, reviews, and walkthroughs featuring CardioLogs ECG Analysis Platform and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing cardiology workflows and EHR systems?

CardioLogs is designed to streamline ECG analysis by integrating with various cardiac monitoring devices and existing ECG management systems, offering a cloud-based platform for analysis and customizable reports. EchoNext, available through the OpenEvidence clinical decision support platform, analyzes standard 12-lead ECGs to detect structural heart disease and aims to integrate into real workflows across health systems.

What are the key differences in the accuracy and sensitivity of these tools?

CardioLogs has demonstrated a sensitivity of 97% and a positive predictive value of 91% for detecting AFib, outperforming conventional methods. EchoNext has shown high accuracy in detecting structural heart disease, with an AUROC of 85.2% in internal tests and 78-80% in external validation, and in studies, it outperformed cardiologists in accuracy (77% vs. 64%).

Which specific cardiac conditions are these tools best suited to detect?

CardioLogs specializes in the rapid and accurate detection of various arrhythmias, such as AFib and VT, from diverse cardiac monitoring devices. EchoNext is designed to detect hidden structural heart disease, including heart failure, valve disease, severe hypertrophy, and pulmonary hypertension, using standard 12-lead ECGs.

What is the learning curve like for physicians adopting these AI tools?

CardioLogs aims to alleviate the burden of redundant ECG analysis tasks, suggesting a focus on efficiency and potentially a reduced learning curve for its core function of arrhythmia detection. EchoNext is intended to augment physician capabilities by identifying patterns cardiologists might miss, implying that while it offers advanced insights, its integration into clinical decision-making would involve understanding its risk scores and implications for further imaging.

What kind of support and resources are available for implementing and using these tools?

CardioLogs, as a Philips solution, offers technical support through its platform and provides documentation like brochures and white papers. EchoNext is available through the OpenEvidence platform, which is used by a large number of US clinicians, suggesting integrated support within that ecosystem.

How do these tools contribute to patient care beyond initial diagnosis, particularly for multi-site rollouts?

CardioLogs facilitates faster diagnostic reporting and can be accessed from any connected computer, supporting collaboration across different facilities and care networks. EchoNext's ability to screen for hidden structural heart disease from routine ECGs could lead to earlier intervention and improved patient outcomes, and its availability on OpenEvidence aims for broad access across various care settings, from major hospitals to community practices.